APLM (Apollomics) Market Cap : $8.77 Mil (As of Mar. 14, 2025)

View and export this data going back to 2023. Start your Free Trial

What is Apollomics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Apollomics's share price for the quarter that ended in Jun. 2024 was $21.09. Apollomics's Shares Outstanding (EOP) for the quarter that ended in Jun. 2024 was 1.10 Mil. Therefore, Apollomics's market cap for the quarter that ended in Jun. 2024 was $23.20 Mil.

Apollomics's quarterly market cap declined from Jun. 2023 ($51,272.61 Mil) to Dec. 2023 ($86.37 Mil) and declined from Dec. 2023 ($86.37 Mil) to Jun. 2024 ($23.20 Mil).

Apollomics's annual market cap stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($86.37 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Apollomics's Enterprise Value for Today is $-12.39 Mil.

Apollomics Market Cap Historical Data

The historical data trend for Apollomics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics Market Cap Chart

Apollomics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Market Cap

86.37

Apollomics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Market Cap	Get a 7-Day Free Trial			-	-	51,272.61	86.37	23.20

Competitive Comparison of Apollomics's Market Cap

For the Biotechnology subindustry, Apollomics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollomics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apollomics's Market Cap distribution charts can be found below:

* The bar in red indicates where Apollomics's Market Cap falls into.

Apollomics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Apollomics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$96.5	*	0.895
	=	$86.37

Apollomics's Market Cap for the quarter that ended in Jun. 2024 is calculated as

Market Cap (Q: Jun. 2024 )	=	Share Price (Q: Jun. 2024 )	*	Shares Outstanding (EOP) (Q: Jun. 2024 )
	=	$21.09	*	1.100
	=	$23.20

Apollomics (NAS:APLM) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Apollomics Market Cap Related Terms

Thank you for viewing the detailed overview of Apollomics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLM) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

APLMW:USA

Address

989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404

Website

https://www.apollomicsinc.com

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.